In April 2005, Clearant completed a reverse merger with Bliss Essentials (OTCBB: BLSE), a producer of handmade soaps. This transaction enabled Clearant to publicly trade. Headquartered in CA with research facilities in MD and in Switzerland, Clearant was a biotechnology company working on a promising pathogen inactivation technology--the Clearant Process® -- that inactivates a range of pathogens, including Human Immunodeficiency Virus, West Nile Virus, and Hepatitis C; provides sterility; and protects the mechanical and biological properties of the biological product being treated. The Clearant Process offered manufacturers of therapeutic protein products the ability to provide inactivation of a spectrum of pathogens at various stages in the manufacturing process, including treatment of source materials, growth media, in-process intermediates, or terminal sterilization of the final product. The company also provides sterilization services to tissue processors as an alternative to complete implementation of the Clearant Process. In addition, it licenses its Clearant Process on a non-exclusive basis to tissue processors and biopharmaceutical companies. Not clear what happened to the firm.
